Plain-English translation of NCT06067698 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether alpha-lipoic acid, a natural compound with anti-inflammatory properties, can help improve ulcerative colitis when taken alongside mesalamine (the standard medication for this condition). Researchers believe this medication may reduce gut inflammation and help patients feel better. You would take either the real treatment or a placebo (inactive pill) in addition to your regular mesalamine doses.
Many people with ulcerative colitis don't respond well enough to standard treatment alone, and doctors are looking for safe ways to boost the effectiveness of current medications. This study is testing whether this medication could be a helpful addition for patients who aren't improving enough on treatment by itself.
You would continue taking your regular mesalamine three times daily, and additionally take either the study medication or a placebo once per day. Half the participants receive the real treatment, and half receive placebo — you won't know which one you're getting. The study will likely involve regular check-ins with the research team to monitor your symptoms, disease activity, and how well you're tolerating the treatment.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Egypt
Sponsor
Tanta University
Enrollment target
~60 participants
Started
October 2023
Primary completion
April 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.